Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

ranibizumab

ranibizumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Lucentis SOLUTION, INTRAOCULAR 0.3 mg | 0.5 mg    
Cimerli SOLUTION, INTRAVITREAL 0.3 mg | 0.5 mg    
Byooviz SOLUTION, INTRAVITREAL 0.5 mg    
Comments:

Lucentis orders for macular degeneration should be interchanged to Avastin.

 

Lucentis is formulary restricted to retina surgeons for treatment of retinopathy of prematurity.

 

Lucentis and all ranibizumab biosimilars are classified as therapeutically equivalent and interchangeable for FDA-approved indications and literature supported off-label uses. The most cost-effective agent will be used in a given patient, setting, or time period.

 

Reviewed: October 25, 2006 (Lucentis), July 2024 (Byooviz), October 2024 (Cimerli)

Updated: 23 April 2019 (Lucentis)

Ranibizumab eqrn (CIMERLI) Spotlight - Copy.pdf

Ranibizumab-nuna (BYOOVIZ) Comparison

Last updated: Apr. 2, 2026






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved